1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Pancreatic Cancer: Epidemiology Forecast to 2026

Pancreatic Cancer: Epidemiology Forecast to 2026

  • April 2018
  • 42 pages
  • ID: 5404419
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Pancreatic Cancer: Epidemiology Forecast to 2026

Summary
Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004).Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA, and grow uncontrollably.

These accumulating cells form a tumor.Untreated pancreatic cancer spreads to nearby organs and blood vessels.

Pancreatic adenocarcinoma or pancreatic exocrine cancer is the most common type of pancreatic cancer, and begins in the cells that line the ducts of the pancreas.Rarely, cancer can form in the hormone-producing cells or the neuroendocrine cells of the pancreas.

These types of cancer are called islet cell tumors, pancreatic endocrine cancer, or pancreatic neuroendocrine tumors (PNETs).

In 2016, the 7MM had 149,780 diagnosed incident cases of pancreatic cancer. This is expected to increase to 182,557 diagnosed incident cases by 2026, at an Annual Growth Rate (AGR) of 2.19%. The increase is driven by the aging population in the 7MM. In 2016, the 7MM had 106,133 five-year diagnosed prevalent cases of pancreatic cancer. This is expected to increase to 131,769 diagnosed prevalent cases by 2026, at an AGR of 2.42%. The US had the highest number of diagnosed incident and five-year diagnosed prevalent cases of pancreatic cancer. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

The report "Pancreatic Cancer: Epidemiology Forecast to 2026", provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the following segmentations in ages 15 years and older across the 7MM: diagnosed incident cases of pancreatic cancer (excluding PNETs); five-year diagnosed prevalent cases of pancreatic cancer (excluding PNETs); diagnosed incident cases of pancreatic cancer (excluding PNETs) by cancer stages at diagnosis; diagnosed incident cases of familial pancreatic cancer (excluding PNETs); diagnosed incident cases of familial pancreatic cancer (excluding PNETs) by germline mutations; and diagnosed incident cases of pancreatic cancer (excluding PNETs) by KRAS mutations.

Scope
- The pancreatic cancer Epidemiology Forecast report provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 15 years and older across the 7MM: diagnosed incident cases of pancreatic cancer (excluding PNETs); five-year diagnosed prevalent cases of pancreatic cancer (excluding PNETs); diagnosed incident cases of pancreatic cancer (excluding PNETs) by cancer stages at diagnosis; diagnosed incident cases of familial pancreatic cancer (excluding PNETs); diagnosed incident cases of familial pancreatic cancer (excluding PNETs) by germline mutations; and diagnosed incident cases of pancreatic cancer (excluding PNETs) by KRAS mutations.
- The pancreatic cancer epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Pancreatic Cancer Epidemiology Forecast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
- Quantify patient populations in the global pancreatic cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pancreatic cancer therapeutics in each of the markets covered.
- Understand magnitude of pancreatic cancer population by mutations.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline ...

High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020

High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020SummaryHigh Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase ...

RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020SummaryRAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on